Literature DB >> 15663189

The effects of insulin-like growth factor binding protein-3 (IGFBP-3) on T47D breast cancer cells enriched for IGFBP-3 binding sites.

Suresh Mishra1, Liam J Murphy.   

Abstract

To investigate insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 (IGFBP-3), T47D cells were enriched for a population of cells that expressed binding sites for biotinylated-IGFBP-3 by panning on streptavidin-coated plate. Proliferation of cell enriched for IGFBP-3 binding sites was significantly inhibited by IGFBP-3, whereas IGFBP-3 had no significant effect on the non-enriched cell population. Enriched and non-enriched cells were equally responsive to IGF-I, TGF-beta and EGF. Conditioned medium from enriched cells had less IGFBP-3 than that from non-enriched cells. Cross-linking of biotinylated IGFBP-3 to T47D cell membranes identified complexes with Mr of 32, 80 and 100 kDa. All of these complexes were more abundant in enriched cells compared with the non-enriched cell population. These data demonstrate that despite the anti-proliferative effects of IGFBP-3 it is possible to selectively enriched for cell populations with more abundant IGFBP-3 binding sites. These enriched cells are more responsive to IGFBP-3 and secrete less of this binding protein than non-enriched cells, supporting the concept that IGFBP-3 secretion by human breast cancer cells may function as an autocrine or paracrine modulator of cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15663189     DOI: 10.1023/b:mcbi.0000049368.40558.0a

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  16 in total

Review 1.  Use of mutagenesis to probe IGF-binding protein structure/function relationships.

Authors:  D R Clemmons
Journal:  Endocr Rev       Date:  2001-12       Impact factor: 19.871

2.  The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene.

Authors:  S M Zadeh; M Binoux
Journal:  Endocrinology       Date:  1997-07       Impact factor: 4.736

3.  Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells.

Authors:  M Karas; M Danilenko; D Fishman; D LeRoith; J Levy; Y Sharoni
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

4.  Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells.

Authors:  Jiang Hong; George Zhang; Feng Dong; Matthew M Rechler
Journal:  J Biol Chem       Date:  2002-01-09       Impact factor: 5.157

Review 5.  Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3.

Authors:  K-W Lee; P Cohen
Journal:  J Endocrinol       Date:  2002-10       Impact factor: 4.286

6.  Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity.

Authors:  J M Ricort; M Binoux
Journal:  Endocrinology       Date:  2001-01       Impact factor: 4.736

7.  A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin.

Authors:  C Lalou; C Lassarre; M Binoux
Journal:  Endocrinology       Date:  1996-08       Impact factor: 4.736

8.  Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells.

Authors:  Y Oh; H L Müller; H Pham; R G Rosenfeld
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

9.  Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-independent actions.

Authors:  A D Hollowood; C E H Stewart; C M Perks; J M Pell; T Lai; D Alderson; J M P Holly
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

10.  Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties.

Authors:  W F Mangel; D L Toledo; A M Nardulli; G C Reiner; M J Norman; B S Katzenellenbogen
Journal:  J Steroid Biochem       Date:  1988       Impact factor: 4.292

View more
  4 in total

1.  Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer.

Authors:  Angela R Ingermann; Yong-Feng Yang; Jinfeng Han; Aki Mikami; Amanda E Garza; Lathika Mohanraj; Lingbo Fan; Michael Idowu; Joy L Ware; Ho-Seong Kim; Dae-Yeol Lee; Youngman Oh
Journal:  J Biol Chem       Date:  2010-03-30       Impact factor: 5.157

2.  Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.

Authors:  Seung Hyun Oh; Young Mi Whang; Hye-Young Min; Seung Ho Han; Ju-Hee Kang; Ki-Hoon Song; Bonnie S Glisson; Yeul Hong Kim; Ho-Young Lee
Journal:  Int J Cancer       Date:  2012-03-28       Impact factor: 7.396

3.  Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury.

Authors:  Jennifer L Kielczewski; Ping Hu; Lynn C Shaw; Sergio Li Calzi; Robert N Mames; Tom A Gardiner; Evan McFarland; Tailoi Chan-Ling; Maria B Grant
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

4.  Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.

Authors:  Quanri Jin; Hyo-Jong Lee; Hye-Young Min; John Kendal Smith; Su Jung Hwang; Young Mi Whang; Woo-Young Kim; Yeul Hong Kim; Ho-Young Lee
Journal:  Carcinogenesis       Date:  2014-06-18       Impact factor: 4.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.